The anticancer drug ‘Retevmo Cap (selpercatinib, Lilly Korea)’ has passed redeliberations by the Health Insurance Review and Assessment Service’s Drug Reimbursement Evaluation Committee (DREC). Therefore, the drug is expected to be smoothly listed for reimbursement if it passes drug pricing negotiations with the National Health Insurance Service.

On the 4th, HIRA announced that it had recognized the reimbursement adequacy of Retevmo Cap after deliberations at the 5th 2023 DREC meeting.

Although the agenda had been discussed at the 4th DREC meeting held in April, a conclusion had not been made for Retevmo Cap, and was set to be rediscussed at a further meeting.

Retevmo is